Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $18.40.

NMRA has been the subject of a number of recent research reports. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Neumora Therapeutics in a report on Monday, December 16th. Royal Bank of Canada downgraded Neumora Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price objective for the stock from $29.00 to $4.00 in a research note on Thursday. Finally, Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research note on Thursday.

Insider Activity

In other news, insider Robert A. Lenz sold 5,563 shares of Neumora Therapeutics stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now directly owns 322,966 shares of the company's stock, valued at approximately $4,847,719.66. The trade was a 1.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the business's stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now owns 20,100 shares in the company, valued at $342,303. This represents a 41.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 26.40% of the company's stock.

Institutional Trading of Neumora Therapeutics

A number of large investors have recently added to or reduced their stakes in NMRA. Amalgamated Bank grew its holdings in shares of Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company's stock valued at $29,000 after purchasing an additional 2,402 shares in the last quarter. Quarry LP bought a new position in Neumora Therapeutics during the second quarter valued at $98,000. SkyOak Wealth LLC purchased a new position in shares of Neumora Therapeutics in the 2nd quarter worth $147,000. Principal Financial Group Inc. bought a new stake in shares of Neumora Therapeutics in the 2nd quarter worth about $166,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Neumora Therapeutics during the 3rd quarter valued at about $175,000. Institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Stock Down 81.4 %

NASDAQ:NMRA traded down $8.63 on Thursday, hitting $1.97. The stock had a trading volume of 44,511,355 shares, compared to its average volume of 751,982. The business's 50-day simple moving average is $10.89 and its two-hundred day simple moving average is $11.59. The stock has a market cap of $318.28 million, a price-to-earnings ratio of -1.05 and a beta of 3.34. Neumora Therapeutics has a 52-week low of $1.83 and a 52-week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the firm earned ($1.14) EPS. As a group, equities research analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.